Health Professional Survey - Translation & Implementation

Implementation of Severe Asthma Management

On behalf of the NHMRC Centre of Excellence in Severe Asthma (www.severeasthma.org.au), we request your assistance in completing a short survey regarding the implementation of management strategies for severe asthma. We are seeking feedback from multidisciplinary healthcare professionals in Australia.

The results from this survey will inform expert forum discussions, ongoing research and development of resources to support translation and implementation of new findings into clinical practice. Our goal is to use this information to develop improved standards of care through the NHMRC Centre of Excellence in Severe Asthma.

This survey consists of 15 questions and we anticipate it will take less than 10 minutes to complete.

If you can submit your responses by Friday 02 November 2018 it will be greatly appreciated.

Thank you and kind regards,
Profs. Peter Gibson, Vanessa McDonald and John Upham, on behalf of the Centre of Excellence in Severe Asthma

This survey has been approved by the HNELHD HREC under authorisation number AU201809-09. All responses are completely anonymous and will be kept strictly confidential. If you experience any issues or have any questions, please contact: severeasthma@newcastle.edu.au

Question Title

* 1. Which title best describes your position?

General Practitioner

Respiratory Specialist (Staff Specialist)

Private Respiratory Physician

Medical Trainee

Respiratory Scientist

Respiratory Nurse Specialist / Consultant

Nurse

Pharmacist

Physiotherapist

Speech Pathologist

Dietician

Psychologist

Asthma Educator

Allergist

Other (please specify)

Question Title

* 2. In what setting do you interact with patients with severe asthma?

Community health centre

General practice

Private medical clinic

General respiratory clinic

Severe asthma clinic

Public hospital

Private hospital

Non-government organisation

Consumer support organisation

Other (please specify)

Question Title

* 3. In what setting do you interact with patients with severe asthma?

Urban

Rural

Question Title

* 4. Approximately how many patients with severe asthma have you treated in the last 3 months?

Question Title

* 5. Do you use a standard checklist to diagnose and assess severe asthma?

Yes

Question Title

* 6. If you use a standard checklist, what was the source?

Not applicable

Developed in-house specifically for clinic

From an external agency / website

From a clinical guideline

Do not know

Question Title

* 7. Please provide additional detail, if you use a standard checklist that was externally sourced:

Question Title

* 8. What proportion of patients did you prescribe/use:

	None (0%)	Few (1-5%)	Some (6-10%)	Many (11-50%)	Most (50-80%)	Nearly all (81-99%)	All (100%)
Bronchial thermoplasty	Bronchial thermoplasty None (0%)	Bronchial thermoplasty Few (1-5%)	Bronchial thermoplasty Some (6-10%)	Bronchial thermoplasty Many (11-50%)	Bronchial thermoplasty Most (50-80%)	Bronchial thermoplasty Nearly all (81-99%)	Bronchial thermoplasty All (100%)
Macrolide antibiotics (e.g. azithromycin)	Macrolide antibiotics (e.g. azithromycin) None (0%)	Macrolide antibiotics (e.g. azithromycin) Few (1-5%)	Macrolide antibiotics (e.g. azithromycin) Some (6-10%)	Macrolide antibiotics (e.g. azithromycin) Many (11-50%)	Macrolide antibiotics (e.g. azithromycin) Most (50-80%)	Macrolide antibiotics (e.g. azithromycin) Nearly all (81-99%)	Macrolide antibiotics (e.g. azithromycin) All (100%)
Monoclonal antibodies (e.g. Xolair/Omalizumab; Nucala/Mepolizumab)	Monoclonal antibodies (e.g. Xolair/Omalizumab; Nucala/Mepolizumab) None (0%)	Monoclonal antibodies (e.g. Xolair/Omalizumab; Nucala/Mepolizumab) Few (1-5%)	Monoclonal antibodies (e.g. Xolair/Omalizumab; Nucala/Mepolizumab) Some (6-10%)	Monoclonal antibodies (e.g. Xolair/Omalizumab; Nucala/Mepolizumab) Many (11-50%)	Monoclonal antibodies (e.g. Xolair/Omalizumab; Nucala/Mepolizumab) Most (50-80%)	Monoclonal antibodies (e.g. Xolair/Omalizumab; Nucala/Mepolizumab) Nearly all (81-99%)	Monoclonal antibodies (e.g. Xolair/Omalizumab; Nucala/Mepolizumab) All (100%)
Phenotyping with blood eosinophils	Phenotyping with blood eosinophils None (0%)	Phenotyping with blood eosinophils Few (1-5%)	Phenotyping with blood eosinophils Some (6-10%)	Phenotyping with blood eosinophils Many (11-50%)	Phenotyping with blood eosinophils Most (50-80%)	Phenotyping with blood eosinophils Nearly all (81-99%)	Phenotyping with blood eosinophils All (100%)
Phenotyping with sputum eosinophils	Phenotyping with sputum eosinophils None (0%)	Phenotyping with sputum eosinophils Few (1-5%)	Phenotyping with sputum eosinophils Some (6-10%)	Phenotyping with sputum eosinophils Many (11-50%)	Phenotyping with sputum eosinophils Most (50-80%)	Phenotyping with sputum eosinophils Nearly all (81-99%)	Phenotyping with sputum eosinophils All (100%)
Phenotyping with fractional exhaled nitric oxides (FeNO)	Phenotyping with fractional exhaled nitric oxides (FeNO) None (0%)	Phenotyping with fractional exhaled nitric oxides (FeNO) Few (1-5%)	Phenotyping with fractional exhaled nitric oxides (FeNO) Some (6-10%)	Phenotyping with fractional exhaled nitric oxides (FeNO) Many (11-50%)	Phenotyping with fractional exhaled nitric oxides (FeNO) Most (50-80%)	Phenotyping with fractional exhaled nitric oxides (FeNO) Nearly all (81-99%)	Phenotyping with fractional exhaled nitric oxides (FeNO) All (100%)

Question Title

* 9. What are the barriers to implementation of these approaches?

Not available

Not convinced about effect/utility

Side effects

Service limitation

Other

Question Title

* 10. Please expand on any barriers to implementation of these approaches:

Question Title

* 11. Does expense of these available treatments / assessments limit your usage in patients?

Yes

Sometimes

Question Title

* 12. Where does your funding for severe asthma management currently come from?

Health service funding

Research funding

Clinical trials

Private healthcare providers

Special purpose funding

Other (please specify)

Question Title

* 13. How often in the last three months have you implemented management of: (Proportion of asthma patients)

	None (0%)	Few (1-5%)	Some (6-10%)	Many (11-50%)	Most (50-80%)	Nearly all (81-99%)	All (100%)
Obesity	Obesity None (0%)	Obesity Few (1-5%)	Obesity Some (6-10%)	Obesity Many (11-50%)	Obesity Most (50-80%)	Obesity Nearly all (81-99%)	Obesity All (100%)
Anxiety	Anxiety None (0%)	Anxiety Few (1-5%)	Anxiety Some (6-10%)	Anxiety Many (11-50%)	Anxiety Most (50-80%)	Anxiety Nearly all (81-99%)	Anxiety All (100%)
Depression	Depression None (0%)	Depression Few (1-5%)	Depression Some (6-10%)	Depression Many (11-50%)	Depression Most (50-80%)	Depression Nearly all (81-99%)	Depression All (100%)
Vocal cord dysfunction (VCD)	Vocal cord dysfunction (VCD) None (0%)	Vocal cord dysfunction (VCD) Few (1-5%)	Vocal cord dysfunction (VCD) Some (6-10%)	Vocal cord dysfunction (VCD) Many (11-50%)	Vocal cord dysfunction (VCD) Most (50-80%)	Vocal cord dysfunction (VCD) Nearly all (81-99%)	Vocal cord dysfunction (VCD) All (100%)
Dysfunctional breathing	Dysfunctional breathing None (0%)	Dysfunctional breathing Few (1-5%)	Dysfunctional breathing Some (6-10%)	Dysfunctional breathing Many (11-50%)	Dysfunctional breathing Most (50-80%)	Dysfunctional breathing Nearly all (81-99%)	Dysfunctional breathing All (100%)
Rhinosinusitis	Rhinosinusitis None (0%)	Rhinosinusitis Few (1-5%)	Rhinosinusitis Some (6-10%)	Rhinosinusitis Many (11-50%)	Rhinosinusitis Most (50-80%)	Rhinosinusitis Nearly all (81-99%)	Rhinosinusitis All (100%)
Obstructive sleep apnoea	Obstructive sleep apnoea None (0%)	Obstructive sleep apnoea Few (1-5%)	Obstructive sleep apnoea Some (6-10%)	Obstructive sleep apnoea Many (11-50%)	Obstructive sleep apnoea Most (50-80%)	Obstructive sleep apnoea Nearly all (81-99%)	Obstructive sleep apnoea All (100%)
Osteoporosis	Osteoporosis None (0%)	Osteoporosis Few (1-5%)	Osteoporosis Some (6-10%)	Osteoporosis Many (11-50%)	Osteoporosis Most (50-80%)	Osteoporosis Nearly all (81-99%)	Osteoporosis All (100%)

Question Title

* 14. How often in the last 3 months have you referred patients for the management of: (Proportion of asthma patients)

	None (0%)	Few (1-5%)	Some (6-10%)	Many (11-50%)	Most (50-80%)	Nearly all (81-99%)	All (100%)
Obesity	Obesity None (0%)	Obesity Few (1-5%)	Obesity Some (6-10%)	Obesity Many (11-50%)	Obesity Most (50-80%)	Obesity Nearly all (81-99%)	Obesity All (100%)
Anxiety	Anxiety None (0%)	Anxiety Few (1-5%)	Anxiety Some (6-10%)	Anxiety Many (11-50%)	Anxiety Most (50-80%)	Anxiety Nearly all (81-99%)	Anxiety All (100%)
Depression	Depression None (0%)	Depression Few (1-5%)	Depression Some (6-10%)	Depression Many (11-50%)	Depression Most (50-80%)	Depression Nearly all (81-99%)	Depression All (100%)
Vocal cord dysfunction (VCD)	Vocal cord dysfunction (VCD) None (0%)	Vocal cord dysfunction (VCD) Few (1-5%)	Vocal cord dysfunction (VCD) Some (6-10%)	Vocal cord dysfunction (VCD) Many (11-50%)	Vocal cord dysfunction (VCD) Most (50-80%)	Vocal cord dysfunction (VCD) Nearly all (81-99%)	Vocal cord dysfunction (VCD) All (100%)
Dysfunctional breathing	Dysfunctional breathing None (0%)	Dysfunctional breathing Few (1-5%)	Dysfunctional breathing Some (6-10%)	Dysfunctional breathing Many (11-50%)	Dysfunctional breathing Most (50-80%)	Dysfunctional breathing Nearly all (81-99%)	Dysfunctional breathing All (100%)
Rhinosinusitis	Rhinosinusitis None (0%)	Rhinosinusitis Few (1-5%)	Rhinosinusitis Some (6-10%)	Rhinosinusitis Many (11-50%)	Rhinosinusitis Most (50-80%)	Rhinosinusitis Nearly all (81-99%)	Rhinosinusitis All (100%)
Obstructive sleep apnoea	Obstructive sleep apnoea None (0%)	Obstructive sleep apnoea Few (1-5%)	Obstructive sleep apnoea Some (6-10%)	Obstructive sleep apnoea Many (11-50%)	Obstructive sleep apnoea Most (50-80%)	Obstructive sleep apnoea Nearly all (81-99%)	Obstructive sleep apnoea All (100%)
Osteoporosis	Osteoporosis None (0%)	Osteoporosis Few (1-5%)	Osteoporosis Some (6-10%)	Osteoporosis Many (11-50%)	Osteoporosis Most (50-80%)	Osteoporosis Nearly all (81-99%)	Osteoporosis All (100%)

Question Title

* 15. How does your management address comorbidities?

Referrals to specific disciplines

Allied health team approach

Guided by standardised questionnaires

No process

Other (please specify)